Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.

Becky Jubb,Marilyn Lewis,Lynn McFadyen,Paul Simpson,Julie Mori,Phylinda Chan,Barry Weatherley,Elna van der Ryst,Mike Westby,Charles Craig

Antiviral chemistry & chemotherapy（2019）

引用 3|浏览27

暂无评分

摘要

Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pr...

查看译文

关键词

AIDS,HIV,drug resistance,mutations

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要